FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 680 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... October 30, 2024 Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... December 6, 2023 Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients... December 1, 2021 Pregnant Mom Experiencing Severe Leg And Back Pain Diagnosed With Stage... February 11, 2020 Load more HOT NEWS How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy Could A Form of Cell Death Enhance Cancer Immunotherapy? Two Women With Terminal Breast Cancer Started A Podcast That’s Unflinchingly... FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma...
